Business
Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million
Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones
About this update from Enovis Corporation
[{"type":"image","alt":"Enovis Corporation","displaySize":"","headline":null,"caption":"Enovis Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":73,"url":"https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/qc6jvQoTNwKdaM8z5d_s_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/04c85b7575377030906937c34935ae92","width":300,"height":73}},"lazy":false},{"type":"text","content":"Wilmington, DE, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (“Enovis” or “the Company”) (NYSE: ENOV), an innovation-driven medical technology growth company, today announced the sale of its Dr. Comfort diabetic shoe business to Promus Equity Partners, a multi-family asset management firm based in Chicago, for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million, and up to $15 million payable in the future upon the achievement of certain milestones.","length":501,"tagName":"p"},{"type":"text","content":"“This transaction represents a positive outcome for Enovis, our Dr. Comfort business, and Promus Equity Partners,” said Damien McDonald, Enovis’ Chief Executive Officer. “The sale sharpens our focus on Enovis’ core strengths and market leadership in Prevention & Recovery. By streamlining our portfolio we are creating a stronger foundation for the future. This divestiture, along with other initiatives already underway, positions Enovis to expand margins, enhance profitability, and accelerate debt reduction—further strengthening our role as a focused med-tech innovator dedicated to improving patients’ lives.”","length":618,"tagName":"p"},{"type":"text","content":"McDonald added, “I want to thank our dedicated Dr. Comfort associates for driving significant performance improvements while staying true to a long-term commitment to patient outcomes. We are confident that, as part of the Promus Equity Partners portfolio, Dr. Comfort has found an ideal environment to achieve its full potential. This acquisition supports continued growth for the business, creates opportunities for employees, and delivers ongoing benefits to the physicians and patients who rely on these products.”","length":518,"tagName":"p"},{"type":"text","content":"”Promus Equity Partners is thrilled to ...